Cite
HARVARD Citation
Nagahata, Y. et al. (2020). High-dose cytarabine chemotherapy (≥4 g/m2/day) before allogeneic hematopoietic stem cell transplantation for non-core-binding-factor AML in the first complete remission. Leukemia & lymphoma. 61 (13), pp. 3128-3136. [Online].